News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Mizuho has increased its target price for Axsome Therapeutics, Inc. to $316, up from the previous $306. This adjustment indicates a positive outlook from the analyst firm regarding the biopharmaceutical company's future performance.
This article provides a technical analysis of AXIS Capital Holdings Ltd (AXS), indicating its current price momentum score, support and resistance levels for range-bound swing trading. It details various technical indicators like MACD, RSI, and Moving Averages, offering a neutral signal based on today's …
Zacks Research has lowered its earnings per share estimates for Axis Capital for Q3 2026 and subsequent periods, citing weaker near-term expectations. Despite missing recent consensus EPS estimates, the insurance provider saw a 7.4% year-over-year revenue increase, and analysts maintain a "Moderate Buy" rating …
Axsome Therapeutics reported Q2 revenues of US$218m, meeting expectations, but statutory losses per share were higher at US$0.99. Analysts reconfirmed revenue forecasts for 2026 at US$972.9m, a 25% increase, but expanded per-share loss expectations to US$2.62. Despite the mixed outlook, the consensus price target …
Axsome Therapeutics (NASDAQ:AXSM) has received a consensus "Moderate Buy" rating from 22 brokerages, with an average 12-month price target of $267.60, significantly above its current trading price of $214.66. This comes despite the company missing its latest quarterly earnings expectations, reporting a wider loss …
UBS has increased its price target for Axsome Therapeutics (NASDAQ: AXSM) to $280 from $259, while maintaining a Buy rating on the stock. This adjustment reflects UBS's continued positive outlook on the biopharmaceutical company. Separately, Mizuho also adjusted its price target for Axsome Therapeutics …
Zacks Research has cut its Q1 2027 EPS estimate for Axis Capital to $3.25 from $3.40, while also projecting a full-year 2028 EPS of $14.62. Despite this reduction and recent target price cuts by other firms, analyst sentiment for Axis Capital remains a "Moderate …
Quantinno Capital Management LP increased its stake in Axsome Therapeutics (NASDAQ:AXSM) by 77.5% in the first quarter, purchasing an additional 5,019 shares and bringing its total holdings to 11,497 shares valued at $1.94 million. Despite revenue growth driven by Auvelity sales, Axsome Therapeutics missed …
Axsome Therapeutics (AXSM) reported Q2 revenue of US$218.4m, driven by its neurology brands, but also posted a net loss of US$51.3m, causing a slight stock pullback. While revenue growth is strong, particularly from AUVELITY, concerns remain about profitability due to high gross-to-net discounts, rising …
Axsome Therapeutics AXSM incurred a loss of 99 cents per share in the second quarter of 2026, which was in line with the Zacks Consensus Estimate. The company had reported a loss of 97 cents per share in the year-ago quarter. Axsome's total revenues …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Axsome Therapeutics earnings event and why it matters Axsome Therapeutics (AXSM) just reported second quarter 2026 results, with revenue of US$218.38 million and a net …
Morgan Stanley has increased its target price for Axsome Therapeutics, Inc. (AXSM) to $251 from $242. This update reflects an analyst's revised valuation for the company. The article, sourced from Reuters, provides this key financial adjustment.
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Axsome Therapeutics has delivered a very large 5 year return while the current valuation …
Axsome Therapeutics, Inc. reported increased revenue in Q2 2026 but also widened net losses, driven by expanding its CNS portfolio and commercialization efforts. While revenue growth is strong, the growing net loss and cash burn raise concerns for investors regarding the company's ability to …
Earnings Call Insights: Axsome Therapeutics (AXSM) Q2 2026 MANAGEMENT VIEW * "The second quarter was highly productive for Axsome as we grew our commercial business robustly and made important regulatory and clinical progress across our innovative neuroscience pipeline," said "Founder, Chairman, CEO & President …
Axsome Therapeutics (NASDAQ:AXSM) shares rose 2.09% in pre-market trading despite missing Q2 earnings and revenue expectations, as investors focused on robust underlying product growth. The company reported a wider loss of $0.99 per share and revenue of $218.4 million, but sales surged 46% year-over-year, …
Axsome Therapeutics Inc (NASDAQ: AXSM) reported its second-quarter earnings, missing analyst estimates for both EPS and revenue. The company posted an EPS of $-0.99 against an estimated $-0.85, and revenue of $218.37M fell short of the $221.92M consensus. Despite the recent miss, the stock …
Axsome Therapeutics, Inc. (AXSM) reported its Q2 revenue at $218.4 million, falling short of the FactSet estimate of $221.1 million. The company's stock was trading at $219.19 USD with a 3.03% change on August 10, 2026. This earnings flash was published at 07:21 am …
Axsome Therapeutics announced strong financial results for Q2 2026, with total net product revenue increasing 46% year-over-year to $218.4 million, driven by significant growth in sales of AUVELITY, SUNOSI, and SYMBRAVO. The company reported a net loss of $51.3 million but indicated that current …
Axsome Therapeutics reported strong Q2 2026 revenue growth, with total net product revenue increasing 46% year-over-year to $218.4 million, driven by AUVELITY, SUNOSI, and SYMBRAVO sales. Despite this growth, the company posted a net loss of $51.3 million due to higher SG&A expenses from …
Axsome Therapeutics reported strong second-quarter 2026 financial results, with total net product revenue reaching $218.4 million, a 46% year-over-year increase, driven by significant growth in AUVELITY sales. The company also provided a business update highlighting the launch of AUVELITY for agitation associated with Alzheimer’s …
Axsome Therapeutics (AXSM) is considered 25% undervalued with a fair value of $282.51, despite a recent 9% stock decline. The valuation is driven by its expanding CNS portfolio, late-stage clinical programs, and projected rapid revenue growth and margin improvements. However, the company faces risks …
Search by ticker symbol or company name and select a result to open its chart.